The diabetes or weight loss drugs Ozempic, Mounjaro and Wegovy are what everyone has been whispering about at brunch, arguing about in DMs and Googling at 2 a.m. Ozempic (semaglutide), Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4 mg) are not just medical treatments, they are cultural currency. Clinically, they have rewritten the playbook on weight loss. Economically, they have exposed a messy global truth that the same syringe can be a life-changing therapy in one country and an unaffordable luxury in another. The clinical evidence is why these drugs rose from obscurity to headline status. Three trials stand out. Put simply, both drugs work very well. Tirzepatide seems to edge semaglutide on average weight loss while semaglutide has a deep track record (and cardiovascular outcom

See Full Page